Nascent Financial Statements From 2010 to 2024
| NBIO Stock | USD 0.06 0.0002 0.32% |
Check Nascent Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nascent Biotech's main balance sheet or income statement drivers, such as , as well as many indicators such as . Nascent financial statements analysis is a perfect complement when working with Nascent Biotech Valuation or Volatility modules.
Nascent |
Nascent Biotech OTC Stock Return On Asset Analysis
Nascent Biotech's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Nascent Biotech Return On Asset | -0.88 |
Most of Nascent Biotech's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nascent Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Nascent Biotech has a Return On Asset of -0.885. This is 89.89% lower than that of the Healthcare sector and 96.25% lower than that of the Biotechnology industry. The return on asset for all United States stocks is notably higher than that of the company.
Nascent Biotech Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Nascent Biotech's current stock value. Our valuation model uses many indicators to compare Nascent Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Nascent Biotech competition to find correlations between indicators driving Nascent Biotech's intrinsic value. More Info.Nascent Biotech is considered to be number one stock in return on asset category among its peers. It also is considered to be number one stock in profit margin category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Nascent Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Nascent Biotech's OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Nascent Biotech Financial Statements
Nascent Biotech investors utilize fundamental indicators, such as revenue or net income, to predict how Nascent OTC Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. In addition, the company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. Nascent Biotech operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Pair Trading with Nascent Biotech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nascent Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nascent Biotech will appreciate offsetting losses from the drop in the long position's value.Moving against Nascent OTC Stock
| 0.63 | REGN | Regeneron Pharmaceuticals | PairCorr |
| 0.62 | NVO | Novo Nordisk AS | PairCorr |
| 0.62 | NONOF | Novo Nordisk AS | PairCorr |
| 0.57 | QSAM | Qsam Biosciences | PairCorr |
| 0.45 | CSLLY | CSL | PairCorr |
The ability to find closely correlated positions to Nascent Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nascent Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nascent Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nascent Biotech to buy it.
The correlation of Nascent Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nascent Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nascent Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nascent Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Nascent OTC Stock
Nascent Biotech financial ratios help investors to determine whether Nascent OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nascent with respect to the benefits of owning Nascent Biotech security.